Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT Long-term Persistence and Booster Study
NCT01962207Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen in meningococcal disease (4 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 at 10 years and Geometric Mean Titers as Measured by rSBA at 10 years. Started Oct 2013; status: completed.
02
Drugs
Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01962207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962207.